CAH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cardinal Health Inc (CAH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong financial performance, positive analyst sentiment with raised price targets, and stable demand despite market challenges. While there are no immediate trading signals from Intellectia Proprietary Trading Signals, the stock's fundamentals and growth trajectory make it a solid long-term investment.
The stock shows a bullish trend with moving averages in a positive alignment (SMA_5 > SMA_20 > SMA_200). The MACD is above zero and contracting positively, indicating potential upward momentum. RSI is neutral at 43.382, suggesting no overbought or oversold conditions. Key support is at 209.283, and resistance is at 228.337, with the current price near the support level, making it a potential entry point.
Strong Q2 financial performance with revenue up 18.75% YoY, net income up 16.75% YoY, and EPS up 19.39% YoY.
Analysts have consistently raised price targets, with the highest target at $260, reflecting confidence in the company's growth trajectory.
Stable demand despite healthcare policy challenges, as noted by the CFO.
Dividend approval indicates financial stability and shareholder value.
Regular market price dropped by -4.10%, which may indicate short-term selling pressure.
Broader market sentiment is negative, with the S&P 500 down -1.54%.
Cardinal Health reported strong Q2 2026 financials with revenue growth of 18.75% YoY to $65.63 billion, net income up 16.75% YoY to $467 million, and EPS increasing by 19.39% YoY to $1.97. Gross margin also improved by 3.83% YoY to 3.52%, showcasing operational efficiency and profitability.
Analysts are overwhelmingly positive on Cardinal Health, with multiple firms raising price targets post-Q2 earnings. The highest target is $260, and the lowest is $233, with all ratings being Outperform or Buy. Analysts highlight strong execution, growth in pharmaceutical and specialty segments, and upside potential in the second half of 2026.
